CA3205636A1 - Beta-2 microglobulin-deficient cells - Google Patents

Beta-2 microglobulin-deficient cells

Info

Publication number
CA3205636A1
CA3205636A1 CA3205636A CA3205636A CA3205636A1 CA 3205636 A1 CA3205636 A1 CA 3205636A1 CA 3205636 A CA3205636 A CA 3205636A CA 3205636 A CA3205636 A CA 3205636A CA 3205636 A1 CA3205636 A1 CA 3205636A1
Authority
CA
Canada
Prior art keywords
cell
cells
hla
protein
hla class
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3205636A
Other languages
English (en)
French (fr)
Inventor
David W. Russell
Roli K. Hirata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington Center for Commercialization
Original Assignee
University of Washington Center for Commercialization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46051930&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3205636(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Washington Center for Commercialization filed Critical University of Washington Center for Commercialization
Publication of CA3205636A1 publication Critical patent/CA3205636A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/17011—Spumavirus, e.g. chimpanzee foamy virus
    • C12N2740/17041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/17043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
CA3205636A 2011-04-20 2012-04-18 Beta-2 microglobulin-deficient cells Pending CA3205636A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161477474P 2011-04-20 2011-04-20
US61/477,474 2011-04-20
CA2833173A CA2833173C (en) 2011-04-20 2012-04-18 Beta-2 microglobulin-deficient cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2833173A Division CA2833173C (en) 2011-04-20 2012-04-18 Beta-2 microglobulin-deficient cells

Publications (1)

Publication Number Publication Date
CA3205636A1 true CA3205636A1 (en) 2012-10-26

Family

ID=46051930

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3205636A Pending CA3205636A1 (en) 2011-04-20 2012-04-18 Beta-2 microglobulin-deficient cells
CA2833173A Active CA2833173C (en) 2011-04-20 2012-04-18 Beta-2 microglobulin-deficient cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2833173A Active CA2833173C (en) 2011-04-20 2012-04-18 Beta-2 microglobulin-deficient cells

Country Status (6)

Country Link
US (3) US20140134195A1 (enExample)
EP (1) EP2699593B2 (enExample)
JP (5) JP2014513948A (enExample)
CA (2) CA3205636A1 (enExample)
DK (1) DK2699593T4 (enExample)
WO (1) WO2012145384A1 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014513948A (ja) * 2011-04-20 2014-06-19 ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション β２ミクログロブリン欠損細胞
PL2838548T3 (pl) * 2012-04-17 2024-02-05 University Of Washington Through Its Center For Commercialization Komórki z niedoborem hla klasy ii, komórki z niedoborem hla klasy i, zdolne do ekspresji białek hla klasy ii i ich zastosowania
CN114558032B (zh) * 2012-12-21 2025-07-29 安斯泰来再生医药协会 由多能干细胞制备血小板的方法及其组合物
CA2913854A1 (en) * 2013-06-03 2014-12-11 Theravectys Lentiviral vectors containing an mhc class i, mhc class ii, or beta-2 microglobulin upstream promoter sequence
AU2015216875B2 (en) 2014-02-14 2021-02-25 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
MX373460B (es) 2014-03-11 2020-04-07 Cellectis Metodo para generar celulas t compatibles para el trasplante alogenico.
GB201412494D0 (en) 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
KR20170075013A (ko) 2014-10-31 2017-06-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Cart 세포에서 유전자 발현의 변경 및 그의 용도
EP3215623A4 (en) 2014-11-06 2018-09-26 President and Fellows of Harvard College Cells lacking b2m surface expression and methods for allogeneic administration of such cells
EP3229586B1 (en) 2014-12-10 2025-07-30 Regents of the University of Minnesota Genetically modified cells, tissues, and organs for treating disease
CA2988854A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Universal donor stem cells and related methods
EP3519562A4 (en) * 2016-09-29 2020-03-25 Nantkwest, Inc. NK-92 HLA CLASS I DEFICIENT CELLS WITH REDUCED IMMUNOGENICITY
KR20250007053A (ko) * 2017-05-23 2025-01-13 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 타겟화된 치료학적 면역조절을 위한 mhc 클래스 ib 분자와 펩타이드의 조합
US10391156B2 (en) * 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
TW201920249A (zh) 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
EP3684919A1 (en) * 2017-10-19 2020-07-29 Cellectis Targeted gene integration of nk inhibitors genes for improved immune cells therapy
EP3727467A4 (en) * 2017-12-22 2021-12-01 Centivax, Inc. MAJOR HISTOCOMPATIBILITY COMPLEX (CMH) COMPOSITIONS AND CORRESPONDING PROCEDURES FOR USE
EP3754018A4 (en) 2018-02-16 2021-11-24 Kyoto University METHOD OF MANUFACTURING A WEAK ANTIGENT CELL
JP2021513839A (ja) * 2018-02-16 2021-06-03 カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ 改変された多能性幹細胞並びに製造方法及び使用方法
KR102304549B1 (ko) * 2018-05-30 2021-09-27 주식회사 강스템바이오텍 Hla 유전자가 제거된 인간 유도만능줄기세포 유래 중간엽줄기세포 및 그의 제조 방법
CN112955542A (zh) * 2018-07-13 2021-06-11 L·杰罗姆罗 非免疫原性工程化组织及其生产方法和用途
IL280610B2 (en) 2018-08-31 2024-08-01 Wisconsin Alumni Res Found Fabrication of vascular grafts seeded with arterial endothelial cells
AU2019336221B2 (en) 2018-09-07 2025-05-15 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
US10724052B2 (en) 2018-09-07 2020-07-28 Crispr Therapeutics Ag Universal donor cells
WO2020067993A1 (en) * 2018-09-26 2020-04-02 National University Of Singapore Engineered human mesenchymal stromal cells with low immunogenicity, methods and kits of generating the same
US11793834B2 (en) 2018-12-12 2023-10-24 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
SG11202108346WA (en) 2019-02-13 2021-08-30 Beam Therapeutics Inc Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
WO2020206248A1 (en) 2019-04-03 2020-10-08 Precision Biosciences, Inc. Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
TW202115245A (zh) 2019-06-27 2021-04-16 丹麥商諾佛 儂迪克股份有限公司 安全免疫隱形細胞
AU2020340622A1 (en) 2019-09-05 2022-03-03 Crispr Therapeutics Ag Universal donor cells
US11118195B2 (en) 2019-09-05 2021-09-14 Crispr Therapeutics Ag Universal donor cells
CN115279398B (zh) 2019-09-27 2025-07-04 比姆医疗股份有限公司 治疗液态癌症的组合物和方法
AU2020370254B2 (en) * 2019-10-22 2026-04-23 The Trustees Of Columbia University In The City Of New York Transgenic swine, methods of making and uses thereof, and methods of making human immune system mice
JP7618337B2 (ja) * 2020-01-10 2025-01-21 エルジー・ケム・リミテッド Ｍｈｃおよび腫瘍抗原を同時発現する抗原提示細胞を含む組成物およびこれを用いた癌治療
MX2022011245A (es) 2020-03-11 2023-01-11 Bit Bio Ltd Método de generación de células hepáticas.
JP2023525049A (ja) * 2020-05-08 2023-06-14 シアトル・チルドレンズ・ホスピタル・ドゥーイング／ビジネス／アズ・シアトル・チルドレンズ・リサーチ・インスティテュート ナチュラルキラー細胞を標的とするキメラ抗原受容体（ｃａｒ）
WO2021231712A1 (en) * 2020-05-15 2021-11-18 Rxcell Inc. Hypoimmunogenic cells and uses thereof in immune responses
WO2021242935A1 (en) * 2020-05-26 2021-12-02 Cue Biopharma, Inc. Antigen presenting polypeptide complexes and methods of use thereof
WO2022038411A1 (en) 2020-08-19 2022-02-24 Astellas Pharma, Inc. Human non-naturally occurring modified fc region of igg specifically binding to non-naturally occurring modified fc receptor
EP4200023A4 (en) * 2020-08-23 2024-10-30 Applied StemCell, Inc. Hla-f-modified cells and methods
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
WO2022129472A1 (en) 2020-12-18 2022-06-23 Novo Nordisk A/S Safe immuno-stealth cells
WO2022136215A1 (en) 2020-12-21 2022-06-30 Novo Nordisk A/S Safe immuno-stealth cells
US11473060B2 (en) 2020-12-30 2022-10-18 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into NK cells
KR20230146007A (ko) 2020-12-31 2023-10-18 크리스퍼 테라퓨틱스 아게 범용 공여자 세포
TW202246494A (zh) * 2021-01-26 2022-12-01 美商艾姆比斯藥品公司 基因改造肝細胞群
WO2022191216A1 (ja) 2021-03-09 2022-09-15 国立研究開発法人理化学研究所 低免疫原性網膜色素上皮細胞の製造方法
US20240200031A1 (en) * 2021-04-12 2024-06-20 Memorial Sloan Kettering Cancer Center Engineered hla molecules useful for t cell and nk cell activation and expansion
CA3216719A1 (en) 2021-05-03 2022-11-10 Astellas Institute For Regenerative Medicine Methods of generating mature corneal endothelial cells
TW202309268A (zh) 2021-05-07 2023-03-01 安斯泰來再生醫藥協會 產生成熟肝細胞的方法
AU2022299551A1 (en) * 2021-06-23 2024-01-18 Editas Medicine, Inc. Engineered cells for therapy
EP4407028A4 (en) 2021-09-24 2025-08-06 Cira Found METHOD FOR PRODUCING MODIFIED HUMAN INDUCED PLURIPOTENT STEM CELLS
WO2023069480A1 (en) * 2021-10-20 2023-04-27 Vascugen, Inc. Hypoimmune vasculogenic cells
AU2023246279A1 (en) 2022-04-01 2024-11-14 LogoMix, Inc. Cell suitable for gene engineering, cell engineering and cellular medicine, and method for producing same
US20260002124A1 (en) 2022-07-01 2026-01-01 Novo Nordisk A/S Enhancing neuronal differentiation of ventral midbrain neural progenitor cells
TW202417614A (zh) 2022-08-23 2024-05-01 安斯泰來再生醫藥協會 用於治療眼部病症的感光救援細胞（prc）組成物及方法
EP4577223A2 (en) * 2022-08-26 2025-07-02 Beam Therapeutics Inc. Modified allogeneic cells and methods and compositions for the preparation thereof
EP4610277A1 (en) 2022-10-25 2025-09-03 Daiichi Sankyo Company, Limited Method for avoiding immune rejection using agonist for inhibitory kir
EP4619033A1 (en) * 2022-11-17 2025-09-24 The Trustees of Indiana University Novel biomarker and target for treating pulmonary hypertension
CN120898000A (zh) 2023-01-13 2025-11-04 拉维洛克治疗有限责任公司 新的多核苷酸、细胞和方法
EP4735585A1 (en) 2023-06-30 2026-05-06 Novo Nordisk A/S Enhancing neuronal differentiation of neural progenitor cells
CN121941763A (zh) * 2023-09-29 2026-04-28 味之素株式会社 Hla基因修饰细胞
GB202316281D0 (en) * 2023-10-24 2023-12-06 Replay Holdings Inc Methods and compositions for modulating immune cell activity in cellular therapy
WO2025235955A1 (en) * 2024-05-10 2025-11-13 Bluerock Therapeutics Lp Genetically engineered cells for enhanced immune evasion and methods thereof
WO2026035951A2 (en) 2024-08-07 2026-02-12 Legend Biotech Ireland Limited Cells overexpressing cd43 and methods of use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5574205A (en) * 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
WO1991010470A1 (en) 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
WO1992009688A1 (en) 1990-11-21 1992-06-11 Massachusetts Institute Of Technology MICE HAVING β2 MICROGLOBULIN GENE DISRUPTION
AU2661692A (en) 1991-09-19 1993-04-27 President And Fellows Of Harvard College Transgenic mhc class i and class ii antigen-deficient mammals
CA2110946A1 (en) 1992-12-09 1994-06-10 Elazar Rabbani Induction of immunocompatibility by nucleic acid
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
EP0972039A1 (en) 1997-03-25 2000-01-19 Morphogenesis, Inc. Universal stem cells
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
EP0995798A1 (en) 1998-10-24 2000-04-26 Novimmune Sa Transcription factor of MHC class II genes, substances capable of inhibiting this new transcription factor and medical uses of these substances
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
DE10132502A1 (de) 2001-07-05 2003-01-23 Gsf Forschungszentrum Umwelt Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
US20040225112A1 (en) 2003-05-06 2004-11-11 Crew Mark D. Genes encoding single chain human leukocyte antigen E (HLA-E) proteins to prevent natural killer cell-mediated cytotoxicity
FR2856599A1 (fr) 2003-06-30 2004-12-31 Commissariat Energie Atomique Utilisation de compositions contenant une forme soluble d'hla-g dans le traitement de pathologies du sang.
SG146691A1 (en) * 2003-10-08 2008-10-30 Vet Stem Inc Methods of preparing and using stem cell compositions and kits comprising the same
WO2007091078A2 (en) 2006-02-10 2007-08-16 Axordia Limited Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g
US8105831B2 (en) 2007-03-09 2012-01-31 University Of Washington Parvoviral production of HLA homozygous cells
WO2008124142A1 (en) 2007-04-06 2008-10-16 International Stem Cell Corporation Patient-specific stem cell lines derived from human parthenogenetic blastocysts
JP5267969B2 (ja) * 2007-12-04 2013-08-21 学校法人慶應義塾 癌ワクチン
EP2184297A1 (en) * 2008-11-07 2010-05-12 Hla-G Technologies HLA-G polypeptides and pharmaceutical uses thereof
CA3157027A1 (en) 2010-07-21 2012-01-26 Sangamo Therapeutics, Inc. Methods and compositions for modification of a t-cell receptor gene
JP2014513948A (ja) * 2011-04-20 2014-06-19 ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション β２ミクログロブリン欠損細胞
KR102055438B1 (ko) 2012-07-31 2019-12-19 에이지엑스 쎄라퓨틱스, 인크. Hla g-변형된 세포 및 방법

Also Published As

Publication number Publication date
DK2699593T3 (da) 2017-11-13
US11813318B2 (en) 2023-11-14
JP2020202880A (ja) 2020-12-24
CA2833173A1 (en) 2012-10-26
EP2699593A1 (en) 2014-02-26
US20140134195A1 (en) 2014-05-15
US20190381154A1 (en) 2019-12-19
JP2023073426A (ja) 2023-05-25
JP2025010296A (ja) 2025-01-20
JP7260182B2 (ja) 2023-04-18
US20240207378A1 (en) 2024-06-27
DK2699593T4 (da) 2021-02-08
JP2014513948A (ja) 2014-06-19
WO2012145384A1 (en) 2012-10-26
JP2018174946A (ja) 2018-11-15
EP2699593B1 (en) 2017-08-30
EP2699593B2 (en) 2020-11-04
JP7586528B2 (ja) 2024-11-19
CA2833173C (en) 2023-09-05

Similar Documents

Publication Publication Date Title
US20240207378A1 (en) Beta-2 microglobulin-deficient cells
JP7531925B2 (ja) Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用
Gornalusse et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells
Harding et al. Immune-privileged tissues formed from immunologically cloaked mouse embryonic stem cells survive long term in allogeneic hosts
JP2021520211A (ja) 組換え受容体を発現するｔ細胞、関連ポリヌクレオチド、および方法
IL293552A (en) Modulators of the immune escape mechanism for universal cell therapy
KR20220010738A (ko) 조절 t 세포에서 제어된 트랜스진 발현
JP2017516752A (ja) 単離されたドナーｍｈｃ由来ペプチド及びその使用
EP1107796A2 (en) Cells expressing immunoregulatory molecules and uses therefor
JP2024522256A (ja) 免疫寛容を誘導するための合成タンパク質
CN114746152A (zh) Hla-f修饰的细胞和方法
WO2024002279A1 (zh) 免疫兼容型人多能干细胞、其制备方法及应用
TW202532430A (zh) 細胞療法
Nagy Acceptance of allogeneic cell transplants without systemic immune suppression

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230706

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240920

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250117

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250213

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250324

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250528

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250808

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260129